CTSO
Cytosorbents Crp
4.30$
-12.4%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -5.2% | +22.3% | -1.6% | -2.6% | +6.2% | -4.6% | +10.2% | -1.4% | -2.6% | -4.0% | +8.7% | – | |
| – | -26.8% | -9.8% | +10.5% | +75.7% | -106.0% | – | +11.2% | +0.6% | -13.8% | +12.5% | -5.5% | – | |
| – | +9.9% | +37.4% | -5.4% | -30.7% | +108.7% | -33.9% | +9.8% | -2.2% | +2.1% | -9.9% | +15.0% | – | |
| – | +9.1% | -45.1% | -32.4% | +21.9% | -29.9% | +28.2% | -24.1% | -27.3% | +35.4% | -17.5% | +41.8% | – | |
| – | +14.6% | -12.4% | -9.1% | -6.8% | -74.3% | +319.1% | +8.7% | -6.1% | +9.6% | -13.6% | -2.3% | – | |
| – | +23.1% | -21.3% | -12.6% | -11.6% | +51.0% | -24.9% | +3.3% | -8.6% | +12.1% | -14.1% | +5.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +55.1% | -87.3% | +2,607.0% | +226.6% | +6.1% | -3.1% | +1.8% | +4.7% | +15.7% | +14.9% | +1.3% | – | |
| – | – | – | – | – | – | – | – | -283.4% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | -262.8% | – | – | – | – | |
| – | – | – | – | – | – | – | – | -184.1% | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.